Antepartum intravenous immunoglobulin therapy in refractory pemphigoid gestationis: Case report and literature review

Journal of Cutaneous Medicine and Surgery

Volumn 14, Issue 4, 2010, Pages 189-192

  Doiron, Philip ^a   Pratt, Melanie ^b  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; BETAMETHASONE VALERATE; CLOXACILLIN; HUMAN IMMUNOGLOBULIN; PREDNISONE; STEROID;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CASE REPORT; DISEASE EXACERBATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG RESPONSE; FEMALE; GESTATIONAL AGE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LOW DRUG DOSE; MULTIPLE CYCLE TREATMENT; PEMPHIGOID GESTATIONIS; PREGNANCY; PRIORITY JOURNAL; REMISSION; SKIN BIOPSY; STAPHYLOCOCCUS INFECTION;

ADULT; ANTI-INFLAMMATORY AGENTS; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; PEMPHIGOID GESTATIONIS; PREDNISONE; PREGNANCY; PREGNANCY TRIMESTER, SECOND; RETREATMENT;

EID: 77955454601     PISSN: 12034754     EISSN: None     Source Type: Journal    
DOI: 10.2310/7750.2009.09001     Document Type: Article

References (14)

1. Freiman A, Pabby A. Emedicine overview: pemphigoid gestationis. Available at: http://emedicine.medscape.com/article/1063499-overview (accessed June 10, 2009).
2. Shornick JK. Dermatoses of pregnancy. Semin Cutan Med Surg 1998;17:172-81.
3. 3 are the major immunoglobulin subclasses targeting epitopes within the NC16A domain of BP180 in pemphigoid gestationis. J Invest Dermatol 1999;113:140-2.
4. Kelly SE, Black MM, Fleming S. Antigen-presenting cells in the skin and placenta in pemphigoid gestationis. Br J Dermatol 1990;122:593-9. (Pubitemid 20153656)
5. Borthwick GM, Holmes RC, Stirrat GM. Abnormal expression of class II MHC antigens in placentae from patients with pemphigoid gestationis. Placenta 1988;9:81-94.
6. Shornick JK, Stastny P, Gilliam JN. Paternal histocompatibility (HLA) antigens and maternal anti-HLA antibodies in herpes gestationis. J Invest Dermatol 1983;81:407-9. (Pubitemid 14228064)
7. Kelly SE, Black MM, Fleming S. Pemphigoid gestationis: a unique mechanism of initiation of an autoimmune response by MHC class II molecules. J Pathol 1989;158:81-2. (Pubitemid 19129484)
8. Shornick JK, Black MM. Fetal risks in herpes gestationis. J Am Acad Dermatol 1992;26:63-8.
9. Jenkins RE, Hern S, Black MM. Clinical features and management of 87 patients with pemphigoid gestationis. Clin Exp Dermatol 1999;24:255-9. (Pubitemid 29366900)
10. Wojnarowska F, Kirtschig G, Khumalo N. Treatment of subepidermal immunobullous diseases. Clin Dermatol 2001;19:768-77.
11. Hern S, Harman K, Bhogal BS. A severe persistent case of pemphigoid gestationis treated with intravenous immunoglobulins and cyclosporin. Clin Exp Dermatol 1998;23:185-8. (Pubitemid 28539507)
12. Kreuter A, Harati A, Breuckmann F. Intravenous immune globulin in the treatment of persistent pemphigoid gestationis. J Am Acad Dermatol 2004;51:1027-8. (Pubitemid 39593031)
13. Rodrigues Cdos S, Filipe P, Solana Mdel M. Persistent herpes gestationis treated with high-dose intravenous immunoglobulin. Acta Derm Venerol 2007;87:184-6. (Pubitemid 46513214)
14. Jolles S. A review of high-dose intravenous immunoglobulin (hdIVIg) in the treatment of the autoimmune blistering disorders. Clin Exp Dermatol 2001;26:127-31. (Pubitemid 32275702)